Cronos Group (NASDAQ:CRON) Chairman and CEO Mike Gorenstein said the cannabis producer is focused on expanding supply to meet demand in its core markets while remaining disciplined about capital deployment and cautious about relying on regulatory change as an investment thesis.
Canada: supply rationalization and the role of exports
Gorenstein said early in Canada’s legalization cycle the industry experienced significant overbuilding, driven by access to capital and companies trying to “get big before they got good.” He argued that having high volumes of supply did not necessarily translate into “good supply” that consumers wanted, which contributed to shutdowns and financial struggles across the sector.
Spinach brand strategy and new product innovation
Discussing Cronos’ Spinach brand, Gorenstein attributed its growth to starting with consumer demand rather than building supply first and later searching for brands to sell it. He contrasted that approach with companies launching many similar brands and “me-too products.” He said Cronos has emphasized differentiated products that build brand equity, citing SOURZ edibles and the company’s newer vape initiatives.
On Spinach “Puffers,” the company’s entry into the all-in-one vape category, he said the launch followed extended consumer research and R&D rather than moving quickly. He described Puffers as a differentiated device designed around consumer use cases, including a “boost button” to deliver a larger hit, a pocket-friendly form factor, and a texture intended to prevent it from rolling off surfaces. He added that the product is intended to pair this hardware with the same flavors that supported Spinach’s success in 510 vapes.
Gross margin improvement and GrowCo ramp-up
Gorenstein addressed year-over-year gross margin improvement in 2025, while noting fourth-quarter results were lighter than earlier quarters. He attributed the Q4 softness primarily to temporary issues tied to Phase II coming online at Cronos GrowCo, which he described as a 70% capacity ramp-up. Among the factors he cited were a catch-up electricity bill received in January from a government utility, overtime labor and staffing needs during the expansion, and a product mix shift during ramp-up that resulted in more Grade C output than Grade A (including more trim versus flower).
He said he expects the full-year 2025 gross margin to be more representative going forward, excluding the Netherlands, and said the facility should be “dialed in” quickly.
On early learnings from GrowCo’s expansion, Gorenstein said the ramp is largely a scheduling and training challenge—moving product through flower rooms, drying, bulk handling, order fulfillment, and processing—rather than a fundamental change to operations. With additional capacity, he said Cronos expects to relieve allocation pressure that has required trade-offs between Canada and export markets such as Israel and parts of Europe. He added that the extra supply should help the company “fill channels” in its primary market.
Capital deployment, U.S. uncertainty, and the High Tide investment
Gorenstein said Cronos began putting more of its cash to work after focusing for years on R&D and operational execution, arguing it is easier to get good first and then expand than the reverse. He also said less capital is flowing into the cannabis industry now, which has reduced valuation expectations and created opportunities that better meet Cronos’ return thresholds. He described his approach as prioritizing deals that “pencil” and can beat returns available from treasuries.
He said Cronos still has a cash balance “over CAD 800 million” and continues to evaluate accretive opportunities, while describing the U.S. as the biggest long-term opportunity. However, he said he does not like to “bet on regulatory change,” framing U.S. reform as something to act on “when it happens.” Asked about the outlook for U.S. rescheduling, he said it is difficult to predict, but characterized the current administration’s potential actions as more volatile and therefore higher variance—something he views as potentially helpful because outcomes could occur quickly. He also pointed to hemp regulation as an important factor to watch, including the possibility of trade-offs that could affect rescheduling or descheduling discussions.
On Cronos’ investment in High Tide, described as Canada’s largest cannabis retailer, Gorenstein said the decision was driven by viewing it as a strong company and by a desire to preserve independence between retailers and suppliers. He said the investment supports a model where consumer choice is driven by brands rather than ownership structures in the retail channel.
International: Germany, Israel, and the Netherlands acquisition
In Germany, Gorenstein said Cronos is excited long term and sees it as one of Europe’s most important markets, but emphasized that regulatory certainty is the key gating factor for deeper investment. He cited uncertainty around telemedicine and delivery rules, as well as evolving price discovery and supply levels. He said Cronos is building demand and growing in the market while remaining prepared to move when conditions become clearer. On whether High Tide could provide asset-light access to Germany, he said Cronos will pursue whichever partner route best delivers brands to patients, mentioning options such as High Tide, Cansativa, or others.
In Israel, Gorenstein said Cronos has become the clear number-one wholesale brand supplier with roughly 23% share. He said the market has high usage and relatively limited illicit competition, but ongoing security issues have slowed certain reforms. He described operational adaptations to conflict conditions and said the company’s facilities have not been damaged and employees remain safe. Over time, he said patient counts could potentially grow “2 or 3x” compared with other medical markets, though timing depends on national priorities.
Turning to the Netherlands, Gorenstein discussed Cronos’ announced acquisition of CanAdelaar. He acknowledged the market is structured as an “experiment” with an expiration date, but argued the Netherlands’ long history of tolerated retail sales makes it unlikely the country would revert to forcing consumers back to illegal supply chains. He said the program’s goal appears to be building a safer, more transparent supply chain and reducing criminal involvement. He also said CanAdelaar has a structural advantage as the only commercial greenhouse in the program, and that Cronos modeled the deal such that even if the program is not extended, it would still recover its principal.
Gorenstein said Cronos is not approaching CanAdelaar as a cost-synergy deal, but as a platform to transfer its intellectual property, genetics, and product innovation into a new market. He pointed to the potential to introduce categories such as vapes and products like SOURZ, and argued the Netherlands could become a key brand-building market in Europe given its cultural importance and what he described as limited innovation over decades due to the lack of legal investment.
Outside of Canada, the U.S., the Netherlands, Germany, and Israel, he cited the U.K. and Switzerland as markets showing progress, while also mentioning Italy as a market Cronos is monitoring.
In closing remarks, Gorenstein said he believes Cronos is sometimes misunderstood by investors, particularly around the distinction between market capitalization and enterprise value. He also said the company has no debt and described Cronos as a growing, profitable business with increasing profitability and multiple avenues for growth, including organic initiatives, M&A, and share buybacks.
About Cronos Group (NASDAQ:CRON)
Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.
The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.
